How to buy Lyra Therapeutics stock | $9.71

Lyra Therapeutics, Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 33 staff and has a market cap (total outstanding shares value) of USD$146.4 million.

How to buy shares in Lyra Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Lyra Therapeutics. Find the stock by name or ticker symbol: LYRA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Lyra Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$9.71, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Lyra Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Lyra Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Lyra Therapeutics share price

Use our graph to track the performance of LYRA stocks over time.

Lyra Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-25.

Latest market close	USD$9.71
52-week range	USD$8.98 - USD$22
50-day moving average	USD$10.9446
200-day moving average	USD$12.0254
Wall St. target price	USD$26
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Lyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Lyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lyra Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyra Therapeutics price performance over time

Historical closes compared with the close of $9.71 from 2020-12-18

1 week (2021-01-07)	-11.89%
1 month (2020-12-17)	1.46%
3 months (2020-10-16)	-26.10%
6 months (2020-07-16)	-16.37%

1 year (2020-01-13)	N/A
2 years (2019-01-13)	N/A
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Lyra Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-51.21%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$146.4 million

TTM: trailing 12 months

Shorting Lyra Therapeutics shares

There are currently 132,149 Lyra Therapeutics shares held short by investors – that's known as Lyra Therapeutics's "short interest". This figure is 8% down from 143,584 last month.

There are a few different ways that this level of interest in shorting Lyra Therapeutics shares can be evaluated.

Lyra Therapeutics's "short interest ratio" (SIR)

Lyra Therapeutics's "short interest ratio" (SIR) is the quantity of Lyra Therapeutics shares currently shorted divided by the average quantity of Lyra Therapeutics shares traded daily (recently around 102441.08527132). Lyra Therapeutics's SIR currently stands at 1.29. In other words for every 100,000 Lyra Therapeutics shares traded daily on the market, roughly 1290 shares are currently held short.

However Lyra Therapeutics's short interest can also be evaluated against the total number of Lyra Therapeutics shares, or, against the total number of tradable Lyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyra Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lyra Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0234% of the tradable shares (for every 100,000 tradable Lyra Therapeutics shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyra Therapeutics.

Find out more about how you can short Lyra Therapeutics stock.

Lyra Therapeutics share dividends

We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.

Lyra Therapeutics overview

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

• What percentage of Lyra Therapeutics is owned by insiders or institutions?

  Currently 1.398% of Lyra Therapeutics shares are held by insiders and 76.696% by institutions.

• How many people work for Lyra Therapeutics?

  Latest data suggests 33 work at Lyra Therapeutics.

• When does the fiscal year end for Lyra Therapeutics?

  Lyra Therapeutics's fiscal year ends in December.

• Where is Lyra Therapeutics based?

  Lyra Therapeutics's address is: 480 Arsenal Way, Watertown, MA, United States, 02472

• What is Lyra Therapeutics's ISIN number?

  Lyra Therapeutics's international securities identification number is: US55234L1052

• What is Lyra Therapeutics's CUSIP number?

  Lyra Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55234L105